Our results show that the Korean NIC expansion and additional genetic counselor involvement together brought about a significant increase in the number of effective BRCA1/2 mutation tests being provided to newly diagnosed breast cancer patients. The gene discussed is BRCA1; the disease is breast carcinoma.